-
Sulfaphenazole-Derived Sulfonamides for Tuberculosis
2026-09-01
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP2C9 inhibition, a liability associated with drug–drug interactions. Compound 10d combined an MIC of 5.69 μg/mL against M. tuberculosis H37Rv with CYP2C9 inhibition of IC50 >10 μM, providing a useful lead profile for further tuberculosis drug discovery.
-
Ivermectin A2813: Reliable Cell Assay Workflows
2026-09-01
This scenario-driven guide explains how to design, control, and interpret parasite viability and proliferation assays using Ivermectin SKU A2813. It connects solvent compatibility, assay controls, storage, endpoint selection, and supplier documentation to more defensible anti-parasitic research workflows.
-
Syringin: Practical Workflows for RCC Research
2026-08-31
Syringin supports a layered RCC research workflow that connects viability, migration, apoptosis, combination response, and EGFR/PI3K/Akt pathway readouts. This guide translates the reference study into practical assay design, formulation, optimization, and troubleshooting decisions for natural product research.
-
Parthenolide, ROS, and Lymphoid Cancer Apoptosis
2026-08-31
Jorge and colleagues show that parthenolide reduces metabolic activity and promotes apoptosis across diverse B- and T-lineage lymphoid malignancy models, with increased reactive oxygen species, glutathione depletion, and mitochondrial membrane-potential loss. The study’s value lies in combining a resazurin cell viability assay with flow-cytometric and gene-expression measurements to distinguish a general cytotoxic response from cell-line-specific mechanisms.
-
Butylated Hydroxyanisole (BHA) Research Workflow
2026-08-30
Use Butylated hydroxyanisole (BHA) as a controlled redox perturbation, antioxidant comparator, or biomolecule-protection reagent—not as a substitute for mechanistic validation. This workflow connects solvent handling, ROS assay design, orthogonal endpoints, and lessons from peptide-chemistry quality control.
-
DDI2–NFE2L1 Control of Ferroptosis
2026-08-29
This study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteostasis pathway that protects cells from ferroptosis. By combining ubiquitylation proteomics, genetic perturbation, and chemical inhibition, the authors connect ferroptotic stress to proteasome remodeling and define a potential vulnerability for ferroptosis-based cancer strategies.
-
BOP Reagent: Coupling Chemistry for Prodrug Design
2026-08-28
BOP reagent, also called benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate, activates carboxyl groups for synthetic amide bond formation and phenyl ester preparation. Product specifications support dry, cold storage and prompt use of freshly prepared organic-solvent solutions, while the cited OSCC study provides biological context rather than direct evidence of BOP-mediated drug efficacy.
-
Parthenolide, ROS, and Lymphoid Cancer Apoptosis
2026-08-28
Jorge and colleagues show that parthenolide reduces metabolic activity and promotes oxidative-stress-associated apoptosis across diverse B- and T-lineage lymphoid malignancy models. By integrating a resazurin-based cell viability assay with flow cytometry and gene-expression analyses, the study connects redox imbalance, mitochondrial dysfunction, and cell-line-dependent responses to NF-κB inhibition.
-
Resazurin Cell Viability Assay Kit in ROS Studies
2026-08-27
The Resazurin Cell Viability Assay Kit provides a sensitive redox-based readout for cell viability and proliferation. This guide explains how to interpret resazurin signals in ROS-driven apoptosis studies, using lymphoid malignancy research to define sound assay design and validation strategies.
-
Cefepime (BMY-28142) in Reliable Cell Assays
2026-08-27
Learn how to use Cefepime (BMY-28142), SKU BA1013, without confusing antimicrobial effects with mammalian cell viability or cytotoxicity. This scenario-based guide connects storage, assay controls, resistance modeling, neurotoxicity studies, and practical product-selection criteria.
-
ICG001 in Biliary Atresia Fibrosis Research
2026-08-26
Explore how ICG001, a selective Wnt/β-catenin pathway inhibitor, can clarify whether MMP7-driven fibrosis depends on CBP-mediated transcription. This article translates recent biliary atresia findings into a disciplined assay strategy that separates β-catenin localization, adhesion loss, and transcriptional output.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-08-26
Build sensitive, reproducible immunofluorescence, IHC, ICC, and flow cytometry workflows around a Cy3-conjugated secondary antibody for rabbit primary antibodies. The approach translates rheumatoid arthritis mechanism research into practical controls, imaging decisions, and troubleshooting steps without overstating product-specific validation.
-
DMG-PEG2000-NH2 for LNP Workflows
2026-08-25
DMG-PEG2000-NH2 combines a lipid-compatible PEG spacer with a reactive primary amine for modular bioconjugation. This article translates its chemistry into practical liposome, lipid nanoparticle, and siRNA assay workflows while using antimycobacterial SAR research to strengthen payload and safety controls.
-
Erastin and the Translational Logic of Ferroptosis
2026-08-25
Erastin is more than a cytotoxicity reagent: it is a mechanistic probe for redox vulnerability, oncogenic context, and tumor metabolism. This article connects ferroptosis research with translational assay design, the RAS-RAF-MEK signaling pathway, and emerging metabolic nanoregulation strategies while defining practical limits for interpretation.
-
Azathramycin A: A Translational TB Strategy
2026-08-24
Azathramycin A offers a research lens on ribosome-directed antibacterial activity, degradation-aware assay design, and site-of-action pharmacology. This thought-leadership guide translates macrolide exposure–response principles into a disciplined framework for Mycobacterium tuberculosis studies without overstating evidence from other disease models.